We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vnus Medical Technologies (MM) | NASDAQ:VNUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.00 | 0 | 01:00:00 |
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5 |
|
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
Murcray Scott |
2. Issuer Name
and
Ticker or Trading Symbol
VNUS MEDICAL TECHNOLOGIES INC [ VNUS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Principal Accounting Officer |
C/O VNUS MEDICAL TECHNOLOGIES, INC., 5799 FONTANOSO WAY |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
SAN JOSE, CA 95138 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 6/17/2009 | D | 780 (1) | D | $29.00 | 0 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Restricted Stock Units | (2) | 6/17/2009 | D (3) | 7000 (3) | (4) | (4) | Common Stock | 7000 | $0.00 | 0 | D | ||||
Restricted Stock Units | (2) | 6/17/2009 | D (3) | 2250 (3) | (5) | (5) | Common Stock | 2250 | $0.00 | 0 | D | ||||
Restricted Stock Units | (2) | 6/17/2009 | D (3) | 2625 (3) | (6) | (6) | Common Stock | 2625 | $0.00 | 0 | D | ||||
Employee Stock Options (right to buy) | $13.78 | 6/17/2009 | D (7) | 3126 (7) | (8) | 7/2/2017 | Common Stock | 3126 | $0.00 | 0 | D |
Explanation of Responses: | |
( 1) | Represents restricted stock units that vested in full and were canceled pursuant to the Agreement and Plan of Merger, dated as of May 7, 2009, by and among Covidien Group S.a.r.l., VNUS Medical Technologies, Inc. (the "Issuer") and Covidien Delaware Corp. (the "Merger"). At the effective time of the Merger, these restricted stock units vested in full and were canceled in exchange for the right to receive a cash payment of $29.00 for each share into which the vested restricted stock units would otherwise be convertible (without interest and less any applicable withholding taxes). |
( 2) | Prior to the effective time of the Merger, the Reporting Person was entitled to receive one (1) share of common stock for each one (1) restricted stock unit. |
( 3) | These restricted stock units vested in full and were canceled at the effective time of the Merger in exchange for the right to receive a cash payment of $29.00 for each share into which the vested restricted stock units would otherwise be convertible (without interest and less any applicable withholding taxes). |
( 4) | Prior to the effective time of the Merger, the restricted stock units were scheduled to vest in four (4) successive and equal annual installments measured from July 1, 2008. |
( 5) | Prior to the effective time of the Merger, the restricted stock units were scheduled to vest in four (4) successive and equal annual installments measured from November 1, 2007. |
( 6) | Prior to the effective time of the Merger, the restricted stock units were scheduled to vest in four (4) successive and equal annual installments measured from July 2, 2007. |
( 7) | These options were canceled at the effective time of the Merger in exchange for a cash payment of $47,577.72, representing the number of shares of Issuer's common stock underlying such options multiplied by $29.00, less the aggregate exercise price of the options. |
( 8) | Prior to the effective time of the Merger, the shares subject to these options were scheduled to vest over four years, with 25% of the shares vesting on July 2, 2008, and 1/36th of the shares vesting monthly thereafter. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Murcray Scott
C/O VNUS MEDICAL TECHNOLOGIES, INC. 5799 FONTANOSO WAY SAN JOSE, CA 95138 |
|
|
Principal Accounting Officer |
|
Signatures
|
||
/s/ Cindee Van Vleck, Attorney-in-Fact for Scott Murcray | 6/17/2009 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Vnus Medical Technologies (MM) Chart |
1 Month Vnus Medical Technologies (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions